9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
9 citations
,
May 2019 in “Journal of dermatological treatment” Apremilast helps regrow hair in hard-to-treat alopecia areata.
1 citations
,
January 1999 in “The European journal of contraception & reproductive health care” Valette® is an effective birth control pill that also reduces greasy hair and skin.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
November 2024 in “Skin Appendage Disorders” Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
12 citations
,
June 2024 in “JAAD Case Reports” Tirzepatide may improve hair loss by reducing insulin resistance.
October 2023 in “Journal of cystic fibrosis”
1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology” TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
October 2006 in “Urology” Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
2 citations
,
February 2007 in “PubMed” Dutasteride is cheaper than finasteride for treating benign prostatic hyperplasia.
April 2012 in “Dermatology Times E-News” Finasteride must now warn about lasting sexual side effects.
April 2008 in “Sexologies” Knowing about potential side effects can make them more likely to happen.
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
25 citations
,
June 2017 in “Neuropharmacology” Increasing TSPO in the brain reduces anxiety and depression.
The treatment was ineffective in humans.
September 1998 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Intermittent isotretinoin can cause various skin, hair, and nail changes.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
63 citations
,
December 2002 in “Archives of Dermatology” The 308-nm excimer laser is a promising treatment for vitiligo with varying success and mild side effects.
63 citations
,
May 2011 in “Clinical cancer research” The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.
June 2026 in “International Journal of Plant & Soil Science” Bhringaraj is a traditional Indian herb used for hair growth and liver health, but more research is needed to confirm its benefits.
65 citations
,
October 2008 in “Journal of Neuroendocrinology”